BCLI RSI Chart
Last 7 days
13.0%
Last 30 days
-3.7%
Last 90 days
40.5%
Trailing 12 Months
-81.2%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 07, 2024 | lebovits chaim | acquired | 24,816 | 0.3743 | 66,300 | president & ceo |
May 06, 2024 | lebovits chaim | acquired | 50,665 | 0.3753 | 135,000 | president & ceo |
Apr 19, 2024 | lebovits chaim | acquired | 7,798 | 0.5199 | 15,000 | president & ceo |
Apr 18, 2024 | lebovits chaim | acquired | 60,470 | 0.5255 | 115,072 | president & ceo |
Apr 17, 2024 | lebovits chaim | acquired | 70,941 | 0.5457 | 130,000 | president & ceo |
Mar 11, 2024 | yablonka uri | acquired | - | - | 109,426 | evp & chief business officer |
Mar 11, 2024 | lebovits chaim | acquired | - | - | 305,198 | president & ceo |
Mar 11, 2024 | lindborg stacy | acquired | - | - | 241,935 | co-chief executive officer |
Mar 11, 2024 | patlis alla | acquired | - | - | 65,246 | see remarks |
Sep 01, 2023 | lindborg stacy | bought | 20,402 | 1.7741 | 11,500 | co-chief executive officer |
Which funds bought or sold BCLI recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 17, 2024 | Ikarian Capital, LLC | unchanged | - | 26,324 | 50,960 | 0.01% |
May 16, 2024 | JANE STREET GROUP, LLC | new | - | 10,578 | 10,578 | -% |
May 15, 2024 | STATE STREET CORP | unchanged | - | 28,021 | 54,245 | -% |
May 15, 2024 | Royal Bank of Canada | reduced | -41.73 | - | - | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -39.65 | 1,240 | 6,218 | -% |
May 15, 2024 | Steward Partners Investment Advisory, LLC | unchanged | - | 1,225 | 2,372 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | reduced | -5.12 | 277 | 564 | -% |
May 15, 2024 | MORGAN STANLEY | reduced | -22.07 | 8,597 | 22,643 | -% |
May 14, 2024 | NORTHERN TRUST CORP | unchanged | - | 15,982 | 30,939 | -% |
May 14, 2024 | Clearstead Advisors, LLC | new | - | 822 | 822 | -% |
Unveiling BrainStorm Cell Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Date Filed | Form Type | Document | |
---|---|---|---|
Peers (Alternatives to BrainStorm Cell Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
BrainStorm Cell Therapeutics Inc News
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -20.4% | 3,348 | 4,208 | 5,682 | 5,747 | 7,872 | 8,451 | 13,254 | 18,961 | 25,791 | 29,277 | 34,538 | 42,235 | 48,571 | 51,259 | 32,691 | 19,221 | 18,071 | 6,534 | 7,811 | 8,864 | 11,851 |
Current Assets | -33.7% | 1,259 | 1,899 | 1,539 | 1,213 | 2,929 | 3,106 | 7,502 | 12,806 | 19,260 | 23,280 | 27,944 | 35,187 | 41,030 | 43,242 | 30,337 | 16,628 | 15,205 | 3,360 | 4,672 | 5,535 | 8,257 |
Cash Equivalents | -26.1% | 961 | 1,300 | 1,222 | 546 | 2,021 | 772 | 4,144 | 9,005 | 15,151 | 18,856 | 25,695 | 30,565 | 35,933 | 37,829 | 24,770 | 12,153 | 12,471 | 536 | 2,095 | 1,126 | 3,238 |
Net PPE | -9.3% | 622 | 686 | 752 | 799 | 866 | 933 | 1,003 | 1,072 | 1,124 | 1,189 | 1,224 | 1,054 | 1,088 | 1,119 | 950 | 918 | 918 | 960 | 664 | 599 | 611 |
Liabilities | -1.9% | 8,898 | 9,066 | 8,264 | 9,629 | 12,712 | 11,466 | 11,866 | 11,110 | 11,304 | 9,935 | 9,612 | 12,063 | 12,370 | 15,795 | 6,713 | 9,399 | 9,060 | 18,757 | 14,588 | 13,380 | 11,525 |
Current Liabilities | -12.4% | 6,831 | 7,800 | 6,321 | 7,691 | 10,422 | 8,800 | 8,948 | 7,846 | 7,372 | 6,317 | 5,846 | 8,059 | 8,191 | 11,233 | 6,429 | 8,840 | 8,252 | 17,654 | 11,958 | 10,543 | 8,480 |
Shareholder's Equity | -14.2% | -5,550 | -4,858 | - | - | -4,840 | -3,015 | 1,388 | 7,851 | 14,487 | 19,342 | 24,926 | 30,172 | 36,201 | 35,464 | 25,978 | 9,822 | 9,011 | - | - | - | 326 |
Retained Earnings | -1.4% | -218,000 | -215,013 | -209,000 | -208,209 | -202,880 | -197,821 | -193,000 | -186,000 | -179,000 | -173,544 | -167,000 | -162,018 | -155,749 | -149,087 | -137,272 | -132,784 | -125,390 | -117,276 | -109,584 | -103,950 | -99,050 |
Additional Paid-In Capital | 1.3% | 212,967 | 210,258 | 206,957 | 204,431 | 198,144 | 194,910 | 194,295 | 193,900 | 193,495 | 192,990 | 192,384 | 192,294 | 192,054 | 184,655 | 163,238 | 142,594 | 134,389 | 105,042 | 102,796 | 99,423 | 98,325 |
Shares Outstanding | 13.0% | 68,342 | 60,489 | 45,315 | 40,927 | 38,475 | 36,694 | 36,493 | 36,486 | 36,437 | 36,401 | 36,305 | 36,319 | 35,791 | - | - | - | - | - | - | - | - |
Float | - | - | - | - | - | - | - | - | 78,887 | - | - | - | 119,594 | - | - | - | 278,375 | - | - | - | 75,374 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 6.8% | -3,063 | -3,285 | -6,409 | -6,778 | -3,986 | -4,648 | -4,850 | -6,134 | -3,688 | -5,508 | -6,460 | -5,329 | -8,968 | -7,578 | -6,924 | -5,662 | -15,029 | -3,278 | -3,626 | -3,508 | -835 |
Share Based Compensation | - | 170 | - | - | - | 4.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cashflow From Investing | -100.0% | - | 196 | -12.00 | 4.00 | 2,005 | 1,038 | -11.00 | -12.00 | -17.00 | -1,297 | 1,696 | -39.00 | -37.00 | -302 | -86.00 | -2,070 | -1,994 | -345 | 1,439 | 1,391 | 3,131 |
Cashflow From Financing | -24.3% | 2,539 | 3,352 | 7,097 | 5,299 | 3,230 | - | - | - | - | -34.00 | -106 | - | 7,109 | 20,939 | 19,627 | 7,414 | 28,958 | 2,064 | 3,156 | 5.00 | - |
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development, net | $ 961 | $ 2,924 |
General and administrative | 1,513 | 2,227 |
Operating loss | (2,474) | (5,151) |
Financial income, net | 13 | 92 |
Loss on change in fair value of Warrants liability (Note 6) | (940) | |
Net loss | $ (3,401) | $ (5,059) |
Basic net loss per share from continuing operations | $ (0.05) | $ (0.14) |
Diluted net loss per share from continuing operations | $ (0.05) | $ (0.14) |
Weighted average number of shares outstanding used in computing basic net loss per share | 64,738,544 | 36,735,435 |
Weighted average number of shares outstanding used in computing diluted net loss per share | 64,738,544 | 36,735,435 |
INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current Assets: | ||
Cash and cash equivalents | $ 779 | $ 1,300 |
Other accounts receivable | 26 | 51 |
Prepaid expenses and other current assets (Note 4) | 454 | 548 |
Total current assets | 1,259 | 1,899 |
Long-Term Assets: | ||
Prepaid expenses and other long-term assets | 20 | 22 |
Restricted Cash | 182 | 185 |
Operating lease right of use asset (Note 5) | 1,265 | 1,416 |
Property and Equipment, Net | 622 | 686 |
Total Long-Term Assets | 2,089 | 2,309 |
Total assets | 3,348 | 4,208 |
Current Liabilities: | ||
Accounts payables | 4,690 | 4,954 |
Accrued expenses | 636 | 1,240 |
Operating lease liability (Note 5) | 588 | 603 |
Employees related liability | 917 | 1,003 |
Total current liabilities | 6,831 | 7,800 |
Long-Term Liabilities: | ||
Operating lease liability (Note 5) | 533 | 672 |
Warrants liability (Note 6) | 1,534 | 594 |
Total long-term liabilities | 2,067 | 1,266 |
Total liabilities | 8,898 | 9,066 |
Stockholders' Deficit: | ||
Stock capital: (Note 7) Common Stock of $0.00005 par value - Authorized: 100,000,000 shares at March 31, 2024 and December 31, 2023 respectively; Issued and outstanding: 68,447,193 and 60,489,208 shares at March 31, 2024 and December 31, 2023 respectively. | 13 | 13 |
Additional paid-in-capital | 212,967 | 210,258 |
Treasury stocks | (116) | (116) |
Accumulated deficit | (218,414) | (215,013) |
Total stockholders' deficit | (5,550) | (4,858) |
Total liabilities and stockholders' deficit | $ 3,348 | $ 4,208 |